New treatment approach for high-grade serous ovarian cancer using combination therapy
Official title: Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer
Funded at Aprea Therapeutics, INC. · NIH-10784732 · Data updated 2026-11-12
This study is looking at a new treatment for high-grade serous ovarian cancer that could help patients with certain genetic changes, aiming to make existing therapies work better and improve outcomes for those affected.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aprea Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 10, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,134,366 |
| NIH project number | 5R44CA278078-02 |
| Project ID | NIH-10784732 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with high-grade serous ovarian cancer, particularly those with BRCA1/2 mutations or those whose tumors overexpress Cyclin E.
✕Less likely to help
Patients with low-grade serous ovarian cancer or those without the specific genetic mutations targeted by this research may not benefit.
What this research studies
This research focuses on developing a novel combination therapy for high-grade serous ovarian cancer (HGSOC), particularly targeting tumors with BRCA1/2 mutations and those overexpressing Cyclin E. The approach involves using a combination of WEE1 kinase inhibitors and ATR inhibitors to overcome resistance to existing treatments like PARP inhibitors. By understanding the molecular mechanisms behind tumor responses, the research aims to improve treatment efficacy and patient outcomes. Patients with specific genetic profiles may benefit from this innovative therapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with high-grade serous ovarian cancer, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results with similar combination therapies in other cancer types, indicating potential for success in this novel approach.
Where this research is happening
-
Aprea Therapeutics, INC.
Boston, United States Active
Researchers
- Principal investigator: Gilad, Oren — Aprea Therapeutics, INC.
- Study coordinator: Gilad, Oren
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.